WEST FRONT STRATEGIES LLC

Issues related to the Medicare Secondary Payer Act, including HR 6860 and S. 5018, Restore Protections for Dialysis Patients Act; Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments (PATIENT) Act, H.R. 5074/S. 4510; issues related to home dialysis.

Client expense: — · Firm income: $50,000

Matched citations: S. 4510

Issues related to the Medicare Secondary Payer Act, including HR 6860 and S. 5018, Restore Protections for Dialysis Patients Act; Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments (PATIENT) Act, H.R. 5074/S. 4510; issues related to home dialysis.

Client expense: — · Firm income: $50,000

Matched citations: S. 5018

Issues related to pharmacy, military pharmacies, pharmacist provider status, and Medicare reimbursement, including Equitable Community Access to Pharmacist Services Act (H.R. 1770 and S. 2477).

Client expense: — · Firm income: $50,000

Matched citations: H.R. 1770

Issues related to pharmacy, military pharmacies, pharmacist provider status, and Medicare reimbursement, including Equitable Community Access to Pharmacist Services Act (H.R. 1770 and S. 2477).

Client expense: — · Firm income: $50,000

Matched citations: S. 2477

Issues related to drug pricing; issues related to pharmaceutical supply chain; issues related to modernization of prescribing information for physicians and pharmacists; Improved Access to Affordable Medications Act, S. 1120; Increasing Transparency in Generic Drug Applications, S.775 and HR 3839; Part D Formulary Design and Generic Drug Tiering; Prescription Information Modernization Act, HR 1503.

Client expense: — · Firm income: $60,000

Matched citations: HR 1503

Issues related to Inter Partes Review and patent policy generally; Preserve Access to Affordable Generics and Biosimilars Act, S.142; Affordable Prescriptions for Patients Act, S. 150 Issues related to FDA and PTO coordination, including, Interagency Patent Coordination and Improvement Act of 2023, S. 79 and HR 1717, and Medication Affordability and Patent Integrity Act, S.2780 and HR 5429; PREVAIL Act, S.2220 and HR 4370; Patent Eligibility Restoration Act of 2023, S.2140.

Client expense: — · Firm income: $60,000

Matched citations: HR 1717

Issues related to drug pricing; issues related to pharmaceutical supply chain; issues related to modernization of prescribing information for physicians and pharmacists; Improved Access to Affordable Medications Act, S. 1120; Increasing Transparency in Generic Drug Applications, S.775 and HR 3839; Part D Formulary Design and Generic Drug Tiering; Prescription Information Modernization Act, HR 1503.

Client expense: — · Firm income: $60,000

Matched citations: HR 3839

Issues related to Inter Partes Review and patent policy generally; Preserve Access to Affordable Generics and Biosimilars Act, S.142; Affordable Prescriptions for Patients Act, S. 150 Issues related to FDA and PTO coordination, including, Interagency Patent Coordination and Improvement Act of 2023, S. 79 and HR 1717, and Medication Affordability and Patent Integrity Act, S.2780 and HR 5429; PREVAIL Act, S.2220 and HR 4370; Patent Eligibility Restoration Act of 2023, S.2140.

Client expense: — · Firm income: $60,000

Matched citations: HR 4370

Issues related to Inter Partes Review and patent policy generally; Preserve Access to Affordable Generics and Biosimilars Act, S.142; Affordable Prescriptions for Patients Act, S. 150 Issues related to FDA and PTO coordination, including, Interagency Patent Coordination and Improvement Act of 2023, S. 79 and HR 1717, and Medication Affordability and Patent Integrity Act, S.2780 and HR 5429; PREVAIL Act, S.2220 and HR 4370; Patent Eligibility Restoration Act of 2023, S.2140.

Client expense: — · Firm income: $60,000

Matched citations: HR 5429

Issues related to drug pricing; issues related to pharmaceutical supply chain; issues related to modernization of prescribing information for physicians and pharmacists; Improved Access to Affordable Medications Act, S. 1120; Increasing Transparency in Generic Drug Applications, S.775 and HR 3839; Part D Formulary Design and Generic Drug Tiering; Prescription Information Modernization Act, HR 1503.

Client expense: — · Firm income: $60,000

Matched citations: S. 1120

Issues related to Inter Partes Review and patent policy generally; Preserve Access to Affordable Generics and Biosimilars Act, S.142; Affordable Prescriptions for Patients Act, S. 150 Issues related to FDA and PTO coordination, including, Interagency Patent Coordination and Improvement Act of 2023, S. 79 and HR 1717, and Medication Affordability and Patent Integrity Act, S.2780 and HR 5429; PREVAIL Act, S.2220 and HR 4370; Patent Eligibility Restoration Act of 2023, S.2140.

Client expense: — · Firm income: $60,000

Matched citations: S.142

Issues related to Inter Partes Review and patent policy generally; Preserve Access to Affordable Generics and Biosimilars Act, S.142; Affordable Prescriptions for Patients Act, S. 150 Issues related to FDA and PTO coordination, including, Interagency Patent Coordination and Improvement Act of 2023, S. 79 and HR 1717, and Medication Affordability and Patent Integrity Act, S.2780 and HR 5429; PREVAIL Act, S.2220 and HR 4370; Patent Eligibility Restoration Act of 2023, S.2140.

Client expense: — · Firm income: $60,000

Matched citations: S. 150

Issues related to Inter Partes Review and patent policy generally; Preserve Access to Affordable Generics and Biosimilars Act, S.142; Affordable Prescriptions for Patients Act, S. 150 Issues related to FDA and PTO coordination, including, Interagency Patent Coordination and Improvement Act of 2023, S. 79 and HR 1717, and Medication Affordability and Patent Integrity Act, S.2780 and HR 5429; PREVAIL Act, S.2220 and HR 4370; Patent Eligibility Restoration Act of 2023, S.2140.

Client expense: — · Firm income: $60,000

Matched citations: S.2140

Issues related to Inter Partes Review and patent policy generally; Preserve Access to Affordable Generics and Biosimilars Act, S.142; Affordable Prescriptions for Patients Act, S. 150 Issues related to FDA and PTO coordination, including, Interagency Patent Coordination and Improvement Act of 2023, S. 79 and HR 1717, and Medication Affordability and Patent Integrity Act, S.2780 and HR 5429; PREVAIL Act, S.2220 and HR 4370; Patent Eligibility Restoration Act of 2023, S.2140.

Client expense: — · Firm income: $60,000

Matched citations: S.2220

Issues related to Inter Partes Review and patent policy generally; Preserve Access to Affordable Generics and Biosimilars Act, S.142; Affordable Prescriptions for Patients Act, S. 150 Issues related to FDA and PTO coordination, including, Interagency Patent Coordination and Improvement Act of 2023, S. 79 and HR 1717, and Medication Affordability and Patent Integrity Act, S.2780 and HR 5429; PREVAIL Act, S.2220 and HR 4370; Patent Eligibility Restoration Act of 2023, S.2140.

Client expense: — · Firm income: $60,000

Matched citations: S.2780

Issues related to drug pricing; issues related to pharmaceutical supply chain; issues related to modernization of prescribing information for physicians and pharmacists; Improved Access to Affordable Medications Act, S. 1120; Increasing Transparency in Generic Drug Applications, S.775 and HR 3839; Part D Formulary Design and Generic Drug Tiering; Prescription Information Modernization Act, HR 1503.

Client expense: — · Firm income: $60,000

Matched citations: S.775

Issues related to Inter Partes Review and patent policy generally; Preserve Access to Affordable Generics and Biosimilars Act, S.142; Affordable Prescriptions for Patients Act, S. 150 Issues related to FDA and PTO coordination, including, Interagency Patent Coordination and Improvement Act of 2023, S. 79 and HR 1717, and Medication Affordability and Patent Integrity Act, S.2780 and HR 5429; PREVAIL Act, S.2220 and HR 4370; Patent Eligibility Restoration Act of 2023, S.2140.

Client expense: — · Firm income: $60,000

Matched citations: S. 79

Issues relating to patent policy including Inter Partes Review and institution decisions, patent quality, communication between patent examiners and the Patent Trial and Appeal Board (PTAB), PTAB generally, and patent eligibility; Patent Eligibility Restoration Act of 2023 (S. 2140 and HR 9474); Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act (S. 2220 and HR 4370); RESTORE Patent Rights Act of 2024 (S. 4840 and HR 9221).

Client expense: — · Firm income: $40,000

Matched citations: HR 4370

Issues relating to patent policy including Inter Partes Review and institution decisions, patent quality, communication between patent examiners and the Patent Trial and Appeal Board (PTAB), PTAB generally, and patent eligibility; Patent Eligibility Restoration Act of 2023 (S. 2140 and HR 9474); Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act (S. 2220 and HR 4370); RESTORE Patent Rights Act of 2024 (S. 4840 and HR 9221).

Client expense: — · Firm income: $40,000

Matched citations: HR 9221

Issues relating to patent policy including Inter Partes Review and institution decisions, patent quality, communication between patent examiners and the Patent Trial and Appeal Board (PTAB), PTAB generally, and patent eligibility; Patent Eligibility Restoration Act of 2023 (S. 2140 and HR 9474); Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act (S. 2220 and HR 4370); RESTORE Patent Rights Act of 2024 (S. 4840 and HR 9221).

Client expense: — · Firm income: $40,000

Matched citations: HR 9474

Issues relating to patent policy including Inter Partes Review and institution decisions, patent quality, communication between patent examiners and the Patent Trial and Appeal Board (PTAB), PTAB generally, and patent eligibility; Patent Eligibility Restoration Act of 2023 (S. 2140 and HR 9474); Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act (S. 2220 and HR 4370); RESTORE Patent Rights Act of 2024 (S. 4840 and HR 9221).

Client expense: — · Firm income: $40,000

Matched citations: S. 2140